BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Preoperative evaluation of malignancy in intraductal papillary mucinous neoplasms of the pancreas, especially in relation to dysplastic epithelial changes.

BACKGROUND/AIMS: Intraductal papillary mucinous neoplasms have a better prognosis than ductal adenocarcinomas of the pancreas.

The diameters of the tumor, main pancreatic duct and mural nodule were measured on the images.

[MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18613438.001).

[ISSN] 0172-6390

[Journal-full-title] Hepato-gastroenterology

[ISO-abbreviation] Hepatogastroenterology

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Differential diagnosis of pancreatic lesions using endoscopic ultrasound].

The most common pancreatic tumour is the ductal adenocarcinoma.

Many other benign and malignant pancreatic neoplasms have to be recognised and now account for more than 50 % of the pancreatic lesions seen in our daily routine.

An improved differential diagnosis is, therefore, mandatory and will be discussed in this review.

[MeSH-major] Endosonography. Pancreatic Neoplasms / ultrasonography

[MeSH-minor] Biopsy, Fine-Needle. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / ultrasonography. Cell Transformation, Neoplastic / pathology. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / ultrasonography. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / ultrasonography. Cystadenoma, Papillary / pathology. Cystadenoma, Papillary / ultrasonography. Cystadenoma, Serous / pathology. Cystadenoma, Serous / ultrasonography. Diagnosis, Differential. Humans. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / ultrasonography. Pancreas / pathology. Pancreas / ultrasonography. Pancreatic Pseudocyst / pathology. Pancreatic Pseudocyst / ultrasonography. Pancreatitis / pathology. Pancreatitis / ultrasonography. Sensitivity and Specificity

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18537088.001).

[ISSN] 0044-2771

[Journal-full-title] Zeitschrift für Gastroenterologie

[ISO-abbreviation] Z Gastroenterol

[Language] ger

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Germany

[Number-of-references] 212

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.

The prognosis of advanced pancreatic cancer is poor.

We investigated how far a combination of trichostatin A (TSA) and gemcitabine synergizes to inhibit proliferation and promotion of apoptosis of pancreatic adenocarcinoma cells in vitro.

The human pancreatic carcinoma cells YAPC, DANG and Panc-89 and primary human foreskin fibroblasts as non-malignant controls were cultured under standardized conditions and incubated with gemcitabine und TSA alone (10(-4) to 10(-8) M) or together (10(-6) to 10(-7) M).

Combination of TSA and gemcitabine shows promise for treatment of pancreatic cancer in vivo.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Carcinoma / drug therapy. Cell Proliferation / drug effects. Deoxycytidine / analogs & derivatives. Hydroxamic Acids / administration & dosage. Pancreatic Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17671683.001).

[ISSN] 1019-6439

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / Hydroxamic Acids; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0W860991D6 / Deoxycytidine; 3X2S926L3Z / trichostatin A; B76N6SBZ8R / gemcitabine; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Mesothelin has been implicated as a potential ideal target antigen for the development of antigen-specific cancer immunotherapy for the control of mesothelin-expressing cancers such as ovarian cancer, mesothelioma and pancreatic adenocarcinoma.

MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 2000 Feb 15;60(4):1035-42 [10706121.001]

[Cites] Gene Ther. 2007 Jan;14(1):20-9 [16915291.001]

[Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]

[Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5492-7 [10779556.001]

[Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]

[Cites] J Leukoc Biol. 2000 Dec;68(6):793-806 [11129646.001]

[Cites] Cancer Res. 2001 Feb 1;61(3):859-63 [11221870.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11545-50 [11553767.001]

[Cites] Vaccine. 2001 Nov 12;20(3-4):421-9 [11672905.001]

[Cites] Cancer Immunol Immunother. 2001 Sep;50(7):356-60 [11676395.001]

[Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]

[Cites] Semin Oncol. 2002 Feb;29(1):41-50 [11836668.001]

[Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]

[Cites] Anticancer Res. 2001 Sep-Oct;21(5):3677-84 [11848542.001]

[Cites] Gene Ther. 2002 Feb;9(3):208-13 [11859424.001]

[Cites] Immunology. 2002 Sep;107(1):39-45 [12225361.001]

[Cites] Front Biosci. 2003 Jan 1;8:d55-68 [12456324.001]

[Cites] Nat Med. 2002 Dec;8(12):1369-75 [12415261.001]

[Cites] Nat Med. 2003 Jan;9(1):33-9 [12496961.001]

[Cites] Cancer Res. 2003 Feb 1;63(3):600-7 [12566302.001]

[Cites] J Immunol. 2003 Mar 15;170(6):3162-70 [12626574.001]

[Cites] Curr Opin Mol Ther. 2003 Feb;5(1):20-4 [12669466.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8850-5 [12857959.001]

[Cites] Int J Cancer. 2003 Dec 20;107(6):976-83 [14601058.001]

[Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]

[Cites] IDrugs. 2003 Dec;6(12):1155-64 [14666426.001]

[Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]

[Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]

[Cites] Immunity. 1995 Aug;3(2):165-9 [7648389.001]

[Cites] Annu Rev Immunol. 1997;15:617-48 [9143702.001]

[Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]

[Cites] Clin Cancer Res. 2005 May 15;11(10):3814-20 [15897581.001]

[Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31 [16467095.001]

[Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]

[Cites] Vaccine. 2007 Jan 2;25(1):127-35 [16930783.001]

[Cites] Int J Cancer. 2000 Apr 1;86(1):89-94 [10728600.001]

(PMID = 17581599.001).

[ISSN] 0969-7128

[Journal-full-title] Gene therapy

[ISO-abbreviation] Gene Ther.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U19 CA113341; United States / NCI NIH HHS / CA / 1U19 CA113341-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Vaccines, DNA; 0 / mesothelin

[Other-IDs] NLM/ NIHMS321551; NLM/ PMC3182456

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.

BACKGROUND: Erlotinib, in combination with gemcitabine, has shown clinical benefits in pancreatic adenocarcinoma patients.

The presence of EGFR mutations and increased EGFR copy numbers in pancreatic adenocarcinoma was explored.

METHODS: Sixty-six pancreatic cancer patients were included in the analysis.

RESULTS: In the current study the EGFR mutation was harbored in only 1 (1.5%) of the 66 inoperable or metastatic pancreatic adenocarcinoma patients.

There was only 1 patient, who had a highly increased EGFR copy number (> or =6.0 per cell), who died, 2.1 months from the date of diagnosis.

The EGFR amplification did not significantly influence survival in pancreatic adenocarcinoma patients (P = .935).

Thirty-two (49%) of the 65 pancreatic adenocarcinomas examined harbored a point mutation in codons 12 (n = 31) and 61 (n = 1) of the KRAS gene.

The presence of a point mutation in codon 12 adversely influenced survival of pancreatic cancer patients (P = .030).

[MeSH-major] Adenocarcinoma / genetics. Genes, ras. Pancreatic Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17354229.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas.

Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease, which is usually diagnosed in an advanced stage.

We believe this is the first report of a pancreas tumor animal model in which pre-symptomatic lesions can be diagnosed.

[MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Pancreatic Ductal / diagnosis. Membrane Glycoproteins / blood. Pancreatic Neoplasms / diagnosis

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

National BioResource Project. culture/stock collections - NBRP resources .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19818733.001).

[ISSN] 1090-2104

[Journal-full-title] Biochemical and biophysical research communications

[ISO-abbreviation] Biochem. Biophys. Res. Commun.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intraductal papillary mucinous neoplasms of the pancreas.

The introduction of the exocrine pancreatic classification by the World Health Organization and improvements in pancreatic imaging have led to an improved understanding of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.

As a result, IPMNs of the pancreas are increasingly being recognized as a separate disease entity.

IPMNs are characterized by the cystic dilatation of the pancreatic duct and its branches, with papillary projections.

The lymph nodes are involved considerably less frequently than they are in pancreatic adenocarcinoma.

Most patients are symptomatic at diagnosis and require a diagnostic workup similar to that for patients with pancreatic adenocarcinoma.

A mural nodule and a main pancreatic duct diameter greater than 5 mm have been found to be predictors of malignancy.

[MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Pancreatic Ductal. Pancreatic Neoplasms

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2006 S. Karger AG, Basel.

(PMID = 16763389.001).

[ISSN] 1011-7571

[Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre

[ISO-abbreviation] Med Princ Pract

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Switzerland

[Number-of-references] 29

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.

BACKGROUND/AIMS: Pancreatic intraepithelial neoplasia (PanIN) is the most common noninvasive precursor to invasive pancreatic adenocarcinoma.

METHODS: Three candidate miRNAs (miR-21, miR-155, and miR-221) previously reported as overexpressed in pancreatic cancers were assessed in 31 microdissected PanINs (14 PanIN-1, 9 PanIN-2, 8 PanIN-3) using quantitative reverse transcription PCR (qRT-PCR).

CONCLUSIONS: Abnormalities of miRNA expression are observed in the multistep progression of pancreatic cancer, with miR-155 aberrations demonstrable at the stage of PanIN-2, and miR-21 abnormalities at the stage of PanIN-3 lesions. and IAP.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]

[Cites] Mol Cell Biol. 2008 Nov;28(22):6773-84 [18794355.001]

[Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]

[Cites] J Mol Diagn. 2008 Mar;10(2):111-22 [18258927.001]

[Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]

[Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]

[Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]

[Cites] PLoS One. 2008;3(7):e2557 [18596939.001]

[Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]

[Cites] J Gastrointest Surg. 2008 Dec;12(12):2171-6 [18642050.001]

[Cites] World J Surg. 2009 Apr;33(4):698-709 [19030927.001]

[Cites] Br J Cancer. 2009 Mar 24;100(6):1002-11 [19293812.001]

[Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]

[Cites] Pancreatology. 2009;9(1-2):66-72 [19077456.001]

[Cites] J Cell Mol Med. 2009 Sep;13(9B):3918-28 [19228262.001]

[Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]

[Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]

[Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]

[Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]

[Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]

[Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]

[Cites] Nat Rev Genet. 2004 Jul;5(7):522-31 [15211354.001]

[Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]

[Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]

[Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]

[Cites] Oncology (Williston Park). 2005 Mar;19(3):393-404, 409; discussion 409-10, 412-6 [15828554.001]

[Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]

[Cites] Mod Pathol. 2005 Jul;18(7):959-63 [15832197.001]

[Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]

[Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]

[Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]

[Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]

[Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]

[Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]

[Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]

[Cites] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803.001]

[Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]

[Cites] Cancer Res. 2007 Feb 15;67(4):1419-23 [17308078.001]

[Cites] Leuk Lymphoma. 2007 Feb;48(2):410-2 [17325905.001]

[Cites] Mod Pathol. 2007 May;20(5):570-8 [17396143.001]

[Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]

[Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):224-32 [17520196.001]

[Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]

[Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]

[Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]

[Cites] Histopathology. 2007 Oct;51(4):539-46 [17714470.001]

[Cites] Annu Rev Genomics Hum Genet. 2007;8:215-39 [17506656.001]

[Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]

[Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]

[Cites] Cancer Biol Ther. 2007 Aug;6(8):1284-8 [17660710.001]

[Cites] J Biol Chem. 2008 Jan 11;283(2):1026-33 [17991735.001]

(PMID = 20332664.001).

[ISSN] 1424-3911

[Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

[ISO-abbreviation] Pancreatology

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50CA062924

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Switzerland

[Chemical-registry-number] 0 / MIRN155 microRNA, human; 0 / MIRN21 microRNA, human; 0 / MIRN221 microRNA, human; 0 / MicroRNAs

[Other-IDs] NLM/ PMC2865485

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.

BACKGROUND: No therapeutic standard of care exists for patients with advanced pancreatic cancer who progress following first-line treatment with a gemcitabine-based regimen.

There is evidence of synergistic activity between docetaxel and irinotecan, and the combination of these two agents has shown promising efficacy in the first-line setting for advanced pancreatic cancer.

METHODS: Eligible patients with metastatic pancreatic adenocarcinoma were required to have an elevated serum CA19-9 (> 2x ULN) and exposure to one or two prior chemotherapy regimens, including one gemcitabine-based.

CONCLUSIONS: The combination of docetaxel and irinotecan given on a 21-day cycle is associated with excess toxicity in gemcitabine-refractory patients with advanced pancreatic cancer.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / toxicity. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology

Genetic Alliance. consumer health - Pancreatic cancer.

Genetic Alliance. consumer health - Metastatic cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DOCETAXEL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18181045.001).

[ISSN] 1532-4192

[Journal-full-title] Cancer investigation

[ISO-abbreviation] Cancer Invest.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].

Two cases of advanced pancreas cancer were treated with GTX.

A 62-year-old man with pancreas head cancer and 2 liver metastases was treated with GEM 1,000 mg/m(2)/week at weeks 1, 2, and 3, and drug-free week 4 for 3 cycles, but was PD.

A 75-year-old man with pancreas head cancer and vascular invasion has been treated with GTX.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Vascular Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Liver Cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

Hazardous Substances Data Bank. DOCETAXEL .

Hazardous Substances Data Bank. CAPECITABINE .

Hazardous Substances Data Bank. FLUOROURACIL .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17197760.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distal pancreatectomy with en bloc resection of the celiac axis for pancreatic adenocarcinoma.

Subsequently, Mayumi et al. and Kimura et al. adopted this approach for locally advanced adenocarcinoma of pancreatic body.

We are here describing this technique in case of adenocarcinoma of pancreatic body with infiltration of celiac axis achieving also gastric preservation.

CT scan showed a 3 cm mass in the body of pancreas infiltrating the origin of celiac axis, causing obstructive atrophy of pancreatic tail.

Appleby operation can increase the resectability of locally advanced cancer of the body and tail of the pancreas and offers not only a better life quality for patients but also perfect pain relief.

[MeSH-major] Adenocarcinoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19795078.001).

[ISSN] 1972-6007

[Journal-full-title] La Clinica terapeutica

[ISO-abbreviation] Clin Ter

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma.

BACKGROUND: Advanced pancreatic cancer has a poor prognosis, and the current standard of care (gemcitabine based chemotherapy) provides a small survival advantage.

This study aimed to evaluate the safety and tolerability of KAb201, an anti-carcinoembryonic antigen monoclonal antibody, labelled with I(131) in pancreatic cancer (ISRCTN 16857581).

METHODS: Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas were randomised to receive KAb 201 via either the intra-arterial or intravenous delivery route.

[MeSH-major] Adenocarcinoma / diagnostic imaging. Carcinoembryonic Antigen / administration & dosage. Immunotoxins / administration & dosage. Iodine Radioisotopes / administration & dosage. Pancreatic Neoplasms / radiotherapy. Radioimmunotherapy / methods

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3232s-3242s [10541369.001]

[Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]

[Cites] Clin Cancer Res. 2000 Feb;6(2):406-14 [10690517.001]

[Cites] Teratog Carcinog Mutagen. 2001;21(1):45-57 [11135320.001]

[Cites] Cancer Res. 2001 Sep 15;61(18):6851-9 [11559561.001]

[Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]

[Cites] Cancer. 2002 Feb 15;94(4 Suppl):1373-81 [11877768.001]

[Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]

[Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]

[Cites] Clin Colorectal Cancer. 2002 May;2(1):31-42 [12453334.001]

[Cites] Aliment Pharmacol Ther. 2003 Dec;18(11-12):1049-69 [14653825.001]

[Cites] Int J Cancer. 2004 Apr 20;109(4):618-26 [14991585.001]

[Cites] J Natl Cancer Inst. 1976 Jul;57(1):11-22 [794493.001]

[Cites] Ann N Y Acad Sci. 1983;417:75-85 [6200051.001]

[Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]

[Cites] Cell. 1989 Apr 21;57(2):327-34 [2702691.001]

[Cites] J Surg Oncol. 1991 Jul;47(3):148-54 [2072697.001]

[Cites] J Nucl Med. 1997 Jun;38(6):858-70 [9189130.001]

[Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]

[Cites] J Nucl Med. 1998 Jan;39(1):34-42 [9443735.001]

[Cites] Hepatogastroenterology. 1998 Jul-Aug;45(22):1125-9 [9756018.001]

[Cites] Hybridoma. 1999 Apr;18(2):183-91 [10380018.001]

[Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]

[Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]

[Cites] Ann Nucl Med. 2005 Jul;19(5):355-65 [16164191.001]

[Cites] J Nucl Med. 2006 Feb;47(2):196-9 [16455623.001]

[Cites] J Nucl Med. 2006 Feb;47(2):247-55 [16455630.001]

[Cites] J Clin Oncol. 2006 Feb 10;24(5):823-34 [16380412.001]

[Cites] J Clin Oncol. 2006 Mar 20;24(9):1395-403 [16505413.001]

[Cites] J Clin Oncol. 2006 Aug 20;24(24):3946-52 [16921047.001]

[Cites] Q J Nucl Med Mol Imaging. 2006 Dec;50(4):248-64 [17043623.001]

[Cites] Curr Drug Discov Technol. 2006 Dec;3(4):231-43 [17430101.001]

[Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]

[Cites] J Clin Oncol. 2007 Jun 20;25(18):2607-15 [17577041.001]

[Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]

(PMID = 19243606.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Databank-accession-numbers] ISRCTN/ ISRCTN16857581

[Grant] United Kingdom / Medical Research Council / / G9900432; United Kingdom / Cancer Research UK / /

[Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Carcinoembryonic Antigen; 0 / Immunotoxins; 0 / Iodine Radioisotopes

[Other-IDs] NLM/ PMC2656541

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.

Treatment of locally advanced pancreatic cancer with high-dose radiotherapy has not been curative, and can be difficult to tolerate.

From December 1993 through May 2001, 107 patients with locally advanced adenocarcinoma of the pancreas had been treated with palliative chemoradiation.

Compared with higher doses given over 5 to 6 weeks, chemoradiation (30 Gy in 10 fractions in 2 weeks with concurrent infusional 5-FU) results in a similar median survival, and local disease progression rates in patients with locally advanced pancreatic cancer apparently do not substantially improve local disease control or median survival time.

[MeSH-major] Adenocarcinoma / radiotherapy. Palliative Care. Pancreatic Neoplasms / radiotherapy. Radiotherapy, High-Energy

MedlinePlus Health Information. consumer health - Palliative Care.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15923793.001).

[ISSN] 1537-453X

[Journal-full-title] American journal of clinical oncology

[ISO-abbreviation] Am. J. Clin. Oncol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA06294; United States / NCI NIH HHS / CA / CA16672

[Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Isolated lymphoplasmacytic sclerosing pancreatitis involving the pancreatic tail.

CT imaging revealed a hypodense lesion in the tail of the pancreas.

Due to concerns of pancreatic malignancy, she underwent operation.

We found a dense, inflammatory mass in the tail of the pancreas, which was removed via an open distal pancreatectomy with splenectomy.

Histologic analysis revealed a pancreas with sclerotic ducts and surrounding lymphoplasmacytic inflammation most consistent with lymphoplasmacytic sclerosing pancreatitis (LPSP).

LPSP, also termed autoimmune pancreatitis, is a benign disease of the pancreas, which can mimic pancreatic adenocarcinoma.

It is the most common benign finding diagnosed on pathology after pancreatic resection for presumed malignancy.

LPSP most commonly involves the head and, more uncommonly, the tail of the pancreas.

[MeSH-major] Pancreas / pathology. Pancreaticoduodenectomy / methods. Pancreatitis / pathology

[MeSH-minor] Chronic Disease. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. Sclerosis

Genetic Alliance. consumer health - Pancreatitis.

MedlinePlus Health Information. consumer health - Pancreatitis.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18646484.001).

[ISSN] 0003-1348

[Journal-full-title] The American surgeon

[ISO-abbreviation] Am Surg

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer.

BACKGROUND: In a previous report we have demonstrated that the chymotryptic-like serine protease kallikrein 7 (KLK7/hK7) is overexpressed in pancreatic cancer.

Thus, the ability of hK7 to degrade desmogleins was assessed and the effect of hK7 expression on desmoglein 2 was examined in cultured pancreatic cancer cells.

METHODS: The expression of Dsg1, Dsg2, and Dsg3 in pancreatic tissues was examined by immunohistochemistry and their expression in two pancreatic cancer cell lines, BxPC-3 and Panc-1, was determined by western blot analysis.

RESULTS: The levels of immunoreactive Dsg1 and Dsg2 were reduced in pancreatic adenocarcinomas compared with both normal pancreatic and chronic pancreatitis tissues.

CONCLUSION: A reduction in the amount of the cell adhesion components Dsg1 and Dsg2 in pancreatic tumors suggests that loss of these desmosomal proteins may play a role in pancreatic cancer invasion.

Using in vitro degradation assays, both Dsg1 and Dsg2 could be readily proteolyzed by hK7, which is overexpressed in pancreatic adenocarcinomas.

The enforced expression of hK7 in BxPC-3 cells that express significant amounts of Dsg2 resulted in a marked increase in the shedding of soluble Dsg2, which is consistent with the notion that aberrant expression of hK7 in pancreatic tumors may result in diminished cell-cell adhesion and facilitate tumor cell invasion.

[MeSH-major] Adenocarcinoma / metabolism. Desmoglein 2 / metabolism. Kallikreins / metabolism. Pancreatic Neoplasms / metabolism

[MeSH-minor] Blotting, Western. Desmoglein 1 / metabolism. Desmoglein 3 / metabolism. Humans. Immunohistochemistry. Pancreas / metabolism. Pancreas / pathology. Pancreatitis / metabolism. RNA, Messenger / metabolism. Recombinant Proteins / metabolism. Tumor Cells, Cultured

Genetic Alliance. consumer health - Pancreatic cancer.

Genetic Alliance. consumer health - Pancreatic cancer 2.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1999 Nov 15;86(10):2074-82 [10570434.001]

[Cites] J Invest Dermatol. 2004 May;122(5):1235-44 [15140227.001]

[Cites] Trends Endocrinol Metab. 2000 Mar;11(2):54-60 [10675891.001]

[Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):208-16 [11252896.001]

[Cites] Pathol Res Pract. 2001;197(2):85-91 [11261822.001]

[Cites] Semin Cancer Biol. 2001 Apr;11(2):143-52 [11322833.001]

[Cites] Biochim Biophys Acta. 2001 Nov 30;1552(1):39-45 [11781114.001]

[Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):454-61 [11906548.001]

[Cites] Exp Dermatol. 2002 Apr;11(2):115-25 [11994138.001]

[Cites] Genes Chromosomes Cancer. 2002 Jul;34(3):255-68 [12007186.001]

[Cites] Clin Chem. 2002 Aug;48(8):1198-205 [12142373.001]

[Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):237-58 [12784999.001]

[Cites] Gynecol Oncol. 2004 Aug;94(2):283-8 [15297163.001]

[Cites] Oncol Rep. 2004 Nov;12(5):1001-6 [15492784.001]

[Cites] Br J Urol. 1990 Feb;65(2):176-80 [2317652.001]

[Cites] Annu Rev Cell Biol. 1990;6:461-91 [2275820.001]

[Cites] Arch Dermatol Res. 1991;283(2):108-12 [1712574.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):353-7 [1729705.001]

[Cites] Breast Cancer Res Treat. 1993;24(3):175-84 [8435473.001]

[Cites] Semin Cancer Biol. 1993 Aug;4(4):219-29 [8400144.001]

[Cites] Semin Cancer Biol. 1993 Aug;4(4):251-8 [8400147.001]

[Cites] Head Neck. 1995 May-Jun;17(3):204-12 [7540167.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]

[Cites] Differentiation. 1996 May;60(2):99-108 [8641550.001]

[Cites] Br J Cancer. 1996 Jun;73(12):1491-7 [8664118.001]

[Cites] Br J Dermatol. 1996 Mar;134(3):460-4 [8731669.001]

[Cites] World J Urol. 1996;14(3):151-6 [8806193.001]

[Cites] J Cell Biol. 1997 Jul 14;138(1):193-201 [9214392.001]

[Cites] J Cell Sci. 1998 Feb;111 ( Pt 4):495-509 [9443898.001]

[Cites] Int Rev Cytol. 1999;185:237-302 [9750269.001]

[Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]

[Cites] Biochem Biophys Res Commun. 2005 Apr 22;329(4):1260-6 [15766562.001]

[Cites] J Pathol. 2005 Oct;207(2):199-206 [16025435.001]

[Cites] J Invest Dermatol. 2006 Jul;126(7):1622-32 [16628198.001]

[Cites] Eur J Cancer. 2006 Sep;42(14):2397-403 [16890424.001]

[Cites] J Biol Chem. 2007 Feb 9;282(6):3640-52 [17158887.001]

[Cites] Cancer. 2007 May 1;109(9):1811-20 [17354228.001]

[Cites] Br J Cancer. 2007 Jun 18;96(12):1783-7 [17519903.001]

[Cites] Am J Pathol. 2007 Sep;171(3):906-16 [17640963.001]

[Cites] Biochem Biophys Res Commun. 2008 May 16;369(4):1169-73 [18343220.001]

[Cites] Virchows Arch. 2003 Jul;443(1):51-6 [12759751.001]

[Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]

(PMID = 19091121.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DSG1 protein, human; 0 / DSG2 protein, human; 0 / DSG3 protein, human; 0 / Desmoglein 1; 0 / Desmoglein 2; 0 / Desmoglein 3; 0 / RNA, Messenger; 0 / Recombinant Proteins; EC 3.4.21.- / KLK7 protein, human; EC 3.4.21.- / Kallikreins

[Other-IDs] NLM/ PMC2628383

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?

We assessed the immunoexpression rates of HepPar-1, CDX2 and MUC2 antibodies in different subtypes of periampullary adenocarcinomas (PAC), intestinal and pancreatobiliary, in order to assess their impact on differential diagnosis of this group of cancers.

The expression of antibodies was also measured in ductal adenocarcinoma of the pancreatic head (DAPH).

METHODS: Sixty-five patients with PAC and DAPH who underwent pancreatic Whipple resection constituted the study cohort.

In addition to CDX2 and MUC2 antibodies, HepPar-1 immunoexpression seems to have a potential role in differential diagnosis of PACs.

[MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Antibodies, Monoclonal / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / metabolism

[MeSH-minor] Adult. Aged. Antigens, Neoplasm / immunology. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Common Bile Duct / metabolism. Common Bile Duct / pathology. Diagnosis, Differential. Female. Homeodomain Proteins / immunology. Homeodomain Proteins / metabolism. Humans. Male. Middle Aged. Mucin-2. Mucins / immunology. Mucins / metabolism. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Retrospective Studies. Sensitivity and Specificity

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18038313.001).

[ISSN] 0031-3025

[Journal-full-title] Pathology

[ISO-abbreviation] Pathology

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In one case, the donor tumor originated from neuroendocrine carcinoma of the pancreas, and in the other case the donor tumor was from adenocarcinoma of the lung.

An awareness of this phenomenon is important to avoid an incorrect diagnosis when encountering unusual morphologic features in renal angiomyolipoma.

[MeSH-minor] Adenocarcinoma / pathology. Aged. Carcinoma, Neuroendocrine / pathology. Humans. Immunohistochemistry. Lung Neoplasms / pathology. Male. Middle Aged. Pancreatic Neoplasms / pathology

MedlinePlus Health Information. consumer health - Kidney Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18517262.001).

[ISSN] 1543-2165

[Journal-full-title] Archives of pathology & laboratory medicine

[ISO-abbreviation] Arch. Pathol. Lab. Med.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.

PURPOSE: The purpose of this Phase II multi-institutional study was to define the efficacy and toxicity of ixabepilone in patients with advance pancreatic adenocarcinoma.

PATIENTS AND METHODS: Patients were required to have pancreatic adenocarcinoma and metastatic or recurrent disease that was not amenable to curative resection.

CONCLUSION: Ixabepilone shows encouraging activity in patients with advanced pancreatic cancer and should be investigated further in this disease.

[MeSH-major] Adenocarcinoma / drug therapy. Epothilones / therapeutic use. Pancreatic Neoplasms / drug therapy. Tubulin Modulators / therapeutic use

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. Ixabepilone .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2004 Sep 15;22(18):3776-83 [15365074.001]

[Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]

[Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]

[Cites] Invest New Drugs. 2005 Oct;23 (5):485-7 [16133800.001]

[Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]

[Cites] J Clin Oncol. 1997 Jun;15(6):2414-9 [9196157.001]

[Cites] J Clin Oncol. 2004 Jul 1;22(13):2610-6 [15226328.001]

[Cites] Invest New Drugs. 1994;12(1):29-34 [7960602.001]

[Cites] Clin Cancer Res. 2001 May;7(5):1429-37 [11350914.001]

[Cites] Cancer. 1999 Mar 15;85(6):1261-8 [10189130.001]

[Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]

[Cites] Br J Cancer. 1996 Jan;73(1):101-5 [8554969.001]

[Cites] Invest New Drugs. 2006 Nov;24(6):515-20 [16699973.001]

(PMID = 16699973.001).

[ISSN] 0167-6997

[Journal-full-title] Investigational new drugs

[ISO-abbreviation] Invest New Drugs

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA27575; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA76429; United States / NCI NIH HHS / CA / CA76447

[Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Epothilones; 0 / Tubulin Modulators; K27005NP0A / ixabepilone

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Precursors to pancreatic cancer].

BACKGROUND: Pancreatic adenocarcinoma is a relatively frequent cancer with an extremely poor prognosis.

Until recently, the natural history of pancreatic adenocarcinoma has not been possible to study, but the identification of precursor lesions (pancreatic intraepithelial neoplasia, PanIN) has lead to a better understanding of the stepwise morphological and genetic alterations involved in the development of invasive adenocarcinoma.

MATERIAL AND METHODS: Relevant literature from the period of 1996-2005 was found by searching the Medline database, combining the terms "pancreas", "cancer", "PanIN" and "neoplasia".

RESULTS AND INTERPRETATION: PanINs are established as designation of histological precursor lesions to pancreatic adenocarcinoma.

PanIN grade I to III represent stepwise morphological alterations in the pancreatic ductal epithelium, from early neoplasia (PanIN I and II), via carcinoma in situ (PanIN III) to the development of invasive ductal adenocarcinoma.

Increased knowledge about pancreatic carcinogenesis may pave the way for prevention strategies, early detection, and new treatment options, thus ultimately improving the prognosis of the patients.

[MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology

Genetic Alliance. consumer health - Pancreatic cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16554881.001).

[ISSN] 0807-7096

[Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række

[ISO-abbreviation] Tidsskr. Nor. Laegeforen.

[Language] nor

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Norway

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Number-of-references] 36

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).

BACKGROUND: The Cancer and Leukemia Group B (CALGB) conducted a phase II study evaluating sunitinib in patients with progressive metastatic pancreas adenocarcinoma following prior gemcitabine-based therapy (trial CALGB 80603; ClinicalTrials.gov identifier, NCT00397787).

PATIENTS AND METHODS: Patients aged ≥18 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and with progressive pancreas adenocarcinoma following treatment with gemcitabine were eligible.

CONCLUSIONS: The study met its primary endpoint; however sunitinib had minimal activity and moderate toxicity in a population of gemcitabine-refractory pancreas adenocarcinoma patients.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Indoles / therapeutic use. Pancreatic Neoplasms / drug therapy. Pyrroles / therapeutic use. Salvage Therapy

Genetic Alliance. consumer health - Pancreatic cancer.

Genetic Alliance. consumer health - Metastatic cancer.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]

[Cites] J Clin Oncol. 2009 Jan 10;27(2):193-8 [19047305.001]

[Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]

[Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]

[Cites] Eur J Cancer. 1998 Aug;34(9):1439-47 [9849429.001]

[Cites] Clin Cancer Res. 2009 Mar 15;15(6):1873-82 [19276273.001]

[Cites] Oncology. 2009;76(4):254-61 [19246950.001]

[Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]

[Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]

[Cites] Curr Drug Metab. 2009 Jun;10(5):470-81 [19689244.001]

[Cites] J Gastrointest Cancer. 2009;40(1-2):1-9 [19513861.001]

[Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1473-85 [19828009.001]

[Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1487-97 [19828010.001]

[Cites] J Clin Oncol. 2010 Aug 1;28(22):3617-22 [20606091.001]

[Cites] Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7 [20130876.001]

[Cites] Ann Oncol. 1999;10 Suppl 4:69-73 [10436789.001]

[Cites] Curr Opin Investig Drugs. 2004 Dec;5(12):1329-39 [15648955.001]

[Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]

[Cites] Invest New Drugs. 2005 Aug;23(4):369-75 [16012797.001]

[Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]

[Cites] Jpn J Clin Oncol. 2007 Feb;37(2):114-20 [17272317.001]

[Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]

[Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]

[Cites] J Clin Oncol. 2007 Oct 20;25(30):4787-92 [17947726.001]

[Cites] J Clin Oncol. 2008 Jan 20;26(3):463-7 [18202421.001]

[Cites] BMC Cancer. 2008;8:82 [18373843.001]

[Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8 [18172650.001]

[Cites] Cancer. 2008 Oct 15;113(8):2046-52 [18756532.001]

[Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):159-66; discussion 166 [11992800.001]

(PMID = 21148613.001).

[ISSN] 1549-490X

[Journal-full-title] The oncologist

[ISO-abbreviation] Oncologist

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00397787

[Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / U10 CA086726; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA045389; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / U10 CA077597; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / U10 CA045418; United States / NCI NIH HHS / CA / CA86726; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / U10 CA047642; United States / NCI NIH HHS / CA / CA31946

[Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib

[Other-IDs] NLM/ PMC3227926

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.

BACKGROUND: Erlotinib is approved for the treatment of advanced pancreas cancer.

We conducted a prospective trial to determine the safety profile and recommended phase 2 dose of erlotinib and capecitabine given concurrently with intensity-modulated radiation therapy (IMRT) in resected pancreatic cancer patients.

METHODS: Patients with resected pancreatic adenocarcinoma received erlotinib and capecitabine concurrently with IMRT delivered at 1.8 Gy daily in 28 fractions (total = 50.4 Gy).

CONCLUSIONS: When administered concurrently with IMRT, erlotinib 100 mg daily and capecitabine 800 mg/m(2) twice daily (Monday to Friday) can be administered safely in resected pancreas cancer patients, and is the recommended regimen for efficacy studies using this regimen.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21151476.001).

[ISSN] 1936-5233

[Journal-full-title] Translational oncology

[ISO-abbreviation] Transl Oncol

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA104900

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC3000462

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT.

RESULTS: The following findings showed significant differences among the three groups: maximum diameter of the main pancreatic duct (MPD), size (length of major axis) of the largest mural nodule in the MPD or in any associated cystic lesion, abnormal attenuating area in the surrounding parenchyma, calcification in the lesion, protrusion of the MPD into the ampulla of Vater, and bile duct dilatation.

[MeSH-major] Adenocarcinoma, Mucinous / radiography. Adenoma / radiography. Pancreatic Neoplasms / radiography. Papilloma, Intraductal / radiography. Radiographic Image Enhancement / methods. Tomography, X-Ray Computed / methods

MedlinePlus Health Information. consumer health - CT Scans.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] RSNA, 2008

(PMID = 18632526.001).

[ISSN] 1527-1315

[Journal-full-title] Radiology

[ISO-abbreviation] Radiology

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Peutz-Jeghers syndrome and duodeno-jejunal adenocarcinoma--therapeutic implications.

Hemminki in 1997 described the presence of LKB-1 mutation tumor-suppressor gen.The patients with PJS develop a higher cumulative incidence of gastrointestinal, pancreas and extraintestinal tumors, being occasion of a renew interest on hamartomatous polyposis syndromes regarding the clinical care, cancer surveillance treatment and long term follow-up.We report the case of a 38 years old male, diagnosed of PJS who developed a multiple adenocarcinoma in duodenum and yeyunum.

[MeSH-major] Adenocarcinoma. Duodenal Neoplasms. Jejunal Neoplasms. Neoplasms, Multiple Primary. Peutz-Jeghers Syndrome / complications

Genetic Alliance. consumer health - Peutz Jeghers syndrome.

MedlinePlus Health Information. consumer health - Intestinal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20082550.001).

[ISSN] 1130-0108

[Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva

[ISO-abbreviation] Rev Esp Enferm Dig

[Language] eng

[Publication-type] Case Reports; Comparative Study; Journal Article

[Publication-country] Spain

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis.

Kazal-type genes are associated with cancer and pancreatic disease.

The aim of the present study was to examine whether ECRG2 STR polymorphisms are associated with pancreatic carcinoma and chronic pancreatitis.

MATERIALS AND METHODS: A total of 209 surgically treated patients were analyzed, 92 with pancreatic adenocarcinoma and 117 with chronic pancreatitis.

RESULTS: ECRG2 STR of highest incidence was TCA3/TCA3 [47 (51%) in pancreatic carcinoma; 59 (50%) in pancreatitis patients], followed by the TCA3/TCA4 [37 (40%); 54 (46%)] and TCA4/TCA4 [8 (9%); 4 (4%)] genotypes.

No correlation in frequency of STRs comparing chronic pancreatitis and pancreatic cancer was determined using the Chi-squared test (p = 0.23).

CONCLUSION: The data show that ECRG2 STR polymorphism TCA3/TCA3 in exon 4 is the most prevalent polymorphism found in pancreatic adenocarcinoma and chronic pancreatitis detected in peripheral blood.

None of the polymorphisms was associated with poor clinical outcome in pancreatic cancer patients.

[MeSH-major] Adenocarcinoma / genetics. Microsatellite Repeats. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics. Tumor Suppressor Proteins / genetics

Genetic Alliance. consumer health - Pancreatitis.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17352218.001).

[ISSN] 0250-7005

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINK7 protein, human; 0 / Tumor Suppressor Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.

BACKGROUND: High mobility group AT-hook 1 (HMGA1) proteins are architectural transcription factors that are overexpressed by pancreatic adenocarcinomas.

The authors hypothesized that tumor HMGA1 status represents a novel prognostic marker in pancreatic adenocarcinoma.

METHODS: Tumor HMGA1 expression was examined by immunohistochemical analysis of tissues from 89 consecutive patients who underwent resection for pancreatic adenocarcinoma.

Short-hairpin RNA (shRNA)-mediated RNA interference was used to silence HMGA1 expression in MiaPaCa2 and PANC1 pancreatic cancer cells.

RESULTS: Tumor HMGA1 expression was detected in 93% of patients with pancreatic adenocarcinoma.

CONCLUSIONS: The current findings suggested that HMGA1 is an independent predictor of poor postoperative survival in patients with pancreatic adenocarcinoma.

HMGA1 warrants further evaluation as a prognostic marker and therapeutic target in pancreatic cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 1990 May 25;265(15):8573-82 [1692833.001]

[Cites] Br J Cancer. 2007 Mar 26;96(6):993-1000 [17342093.001]

[Cites] J Cell Biol. 1994 Feb;124(4):619-26 [8106557.001]

[Cites] Mol Cell Biol. 1995 Mar;15(3):1786-96 [7862168.001]

[Cites] Cell. 1995 Dec 29;83(7):1091-100 [8548797.001]

[Cites] Oncogene. 1997 Jun 19;14(24):2971-7 [9205104.001]

[Cites] Oncogene. 1998 May;16(20):2681-6 [9632144.001]

[Cites] Clin Cancer Res. 2004 Nov 15;10(22):7637-44 [15569996.001]

[Cites] Cancer Res. 2000 Jun 15;60(12):3117-22 [10866296.001]

[Cites] Mol Cell Biol. 2001 Jan;21(2):575-94 [11134344.001]

[Cites] Pancreas. 2002 Jan;24(1):42-6 [11741181.001]

[Cites] Oncogene. 2004 Jan 22;23(3):777-85 [14737112.001]

[Cites] Langenbecks Arch Surg. 2004 Jun;389(3):193-7 [15107999.001]

[Cites] Nature. 2004 Aug 26;430(7003):1034-9 [15329723.001]

[Cites] Cancer Res. 1989 Dec 1;49(23):6543-6 [2819710.001]

[Cites] Biochem Biophys Res Commun. 2005 Sep 30;335(3):949-56 [16105664.001]

[Cites] Dig Dis Sci. 2005 Oct;50(10):1764-70 [16187170.001]

[Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]

[Cites] Cancer Res. 2006 Mar 15;66(6):2980-9 [16540646.001]

[Cites] J Pathol. 2006 Jun;209(2):206-12 [16521118.001]

[Cites] Diabetes. 2006 Sep;55(9):2470-8 [16936195.001]

[Cites] J Gastrointest Surg. 2006 Nov;10(9):1254-62; discussion 1263 [17114012.001]

[Cites] Cancer Res. 2006 Dec 15;66(24):11613-22 [17178855.001]

[Cites] Exp Cell Res. 2007 Jan 1;313(1):77-87 [17045586.001]

[Cites] J Clin Invest. 2007 Mar;117(3):693-702 [17290307.001]

[Cites] Nucleic Acids Res. 1993 Sep 11;21(18):4259-67 [8414980.001]

(PMID = 18473350.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA114103-04; United States / NCI NIH HHS / CA / R01 CA114103; United States / NCI NIH HHS / CA / R01 CA114103-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 124544-67-8 / HMGA1a Protein; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases

[Other-IDs] NLM/ NIHMS253257; NLM/ PMC2997611

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The neurotrophic factor artemin promotes pancreatic cancer invasion.

OBJECTIVE: To analyze the role of Artemin in pancreatic ductal adenocarcinoma (PDAC) in terms of expression, influence on cancer cell behavior, and pain correlation.

METHODS: Artemin and its receptors (GFRalpha3/RET) were studied in PDAC tissues and normal pancreas by Western blot analysis and immunohistochemistry.

RNA expression was analyzed in pancreatic tissues (normal, cancer) and pancreatic cancer cell lines by QRT-PCR.

RESULTS: Artemin and GFRalpha3/RET were both detected at enhanced levels in PDAC compared with normal pancreas, localizing predominantly in hypertrophic nerves and arterial walls, as well as in cancer cells of primary and metastatic lesions.

However, Artemin promoted pancreatic cancer cell invasion up to 5-fold, without affecting cancer cell proliferation.

However by increasing cancer cell invasion, Artemin seems to influence neural invasion and thereby contribute to cancer cell spreading along pancreatic nerves.

[MeSH-major] Adenocarcinoma / pathology. Nerve Growth Factors / physiology. Nerve Tissue Proteins / physiology. Pancreatic Neoplasms / pathology

[MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Proliferation. Coloring Agents. Glial Cell Line-Derived Neurotrophic Factor Receptors / physiology. Humans. Hypertrophy. Immunohistochemistry. Neoplasm Invasiveness. Nerve Regeneration / physiology. Neurons / pathology. Pain / physiopathology. Pancreas / innervation. Pancreas / pathology. Polymerase Chain Reaction. Prospective Studies. Tetrazolium Salts. Thiazoles

Genetic Alliance. consumer health - Pancreatic cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Pancreas. 2003 Aug;27(2):190-6 [12883269.001]

[Cites] Ann Surg. 2005 Jan;241(1):144-51 [15622002.001]

[Cites] Nat Med. 2003 Nov;9(11):1383-9 [14528299.001]

[Cites] Oncogene. 2004 Jan 8;23(1):71-81 [14712212.001]

[Cites] Cancer Res. 2004 Aug 1;64(15):5291-300 [15289335.001]

[Cites] Cancer. 1987 Nov 1;60(9):2284-303 [3326653.001]

[Cites] Ann Surg. 1989 Feb;209(2):181-7 [2464969.001]

[Cites] Gastroenterology. 1991 Feb;100(2):529-36 [1985049.001]

[Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]

[Cites] Science. 1993 May 21;260(5111):1130-2 [8493557.001]

[Cites] Gastroenterology. 1994 Jul;107(1):219-30 [8020665.001]

[Cites] Nature. 1996 Dec 5;384(6608):467-70 [8945474.001]

[Cites] J Biol Chem. 1998 Feb 6;273(6):3502-8 [9452475.001]

[Cites] J Neurosci. 1999 Nov 1;19(21):9322-31 [10531437.001]

[Cites] J Biol Chem. 2000 Feb 4;275(5):3412-20 [10652334.001]

[Cites] Development. 2000 Oct;127(20):4335-44 [11003834.001]

[Cites] Pancreas. 2001 Apr;22(3):279-84 [11291930.001]

[Cites] Eur J Neurosci. 2001 Jun;13(11):2177-82 [11422460.001]

[Cites] Cytokine Growth Factor Rev. 2001 Dec;12(4):361-73 [11544105.001]

[Cites] Development. 2001 Oct;128(19):3685-95 [11585795.001]

[Cites] Development. 2001 Oct;128(20):3963-74 [11641220.001]

[Cites] Pancreas. 2002 Jan;24(1):15-25 [11741178.001]

[Cites] J Biol Chem. 2002 Jan 18;277(3):1991-9 [11713247.001]

[Cites] Neuron. 2002 Jul 18;35(2):267-82 [12160745.001]

[Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]

[Cites] Nat Med. 2003 May;9(5):589-95 [12669033.001]

[Cites] Neuron. 1998 Feb;20(2):245-53 [9491986.001]

[Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5801-6 [9576965.001]

[Cites] J Am Coll Surg. 1998 Jun;186(6):675-82 [9632157.001]

[Cites] J Neurol. 1998 Nov;245(11 Suppl 3):P35-42 [9808338.001]

[Cites] Neuron. 1998 Dec;21(6):1291-302 [9883723.001]

[Cites] Int J Cancer. 1999 Mar 31;81(1):67-73 [10077155.001]

[Cites] Surgery. 2003 Aug;134(2):293-9 [12947332.001]

(PMID = 16858191.001).

[ISSN] 0003-4932

[Journal-full-title] Annals of surgery

[ISO-abbreviation] Ann. Surg.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / ARTN protein, human; 0 / Coloring Agents; 0 / Glial Cell Line-Derived Neurotrophic Factor Receptors; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue

[Other-IDs] NLM/ PMC1602177

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.

BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a highly invasive and metastatic disease for which conventional treatments are of limited efficacy.

Targeting expression of Trp53(R172H) and Kras(G12D) to the mouse pancreas results in the formation of invasive and metastatic PDAC.

[MeSH-major] Carcinoma, Pancreatic Ductal / drug therapy. Pancreatic Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Thiazoles / therapeutic use. src-Family Kinases / antagonists & inhibitors

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

(PMID = 20303350.001).

[ISSN] 1528-0012

[Journal-full-title] Gastroenterology

[ISO-abbreviation] Gastroenterology

[Language] eng

[Grant] United Kingdom / Chief Scientist Office / / CAF/06/24; United Kingdom / Cancer Research UK / / C157/A9148; United Kingdom / Chief Scientist Office / / ; United Kingdom / Cancer Research UK / / C2193/A7603

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.2 / src-Family Kinases; RBZ1571X5H / Dasatinib

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

GALLBLADDER: Ultrasound has become widely accepted for the diagnosis of gallbladder disease.

PANCREAS: In diagnostic imaging of the pancreas ultrasound stands at the beginning of a diagnostic cascade.

Ductal adenocarcinoma seems to be less vascularized in comparison to the surrounding tissue, while endocrine tumors and macro- and microcystic adenoma are rather hypervascularized.

[MeSH-major] Biliary Tract Diseases / ultrasonography. Pancreatic Diseases / ultrasonography

[MeSH-minor] Adenoma / ultrasonography. Bile Duct Neoplasms / ultrasonography. Bile Ducts, Intrahepatic / ultrasonography. Carcinoma / ultrasonography. Cholangiocarcinoma / ultrasonography. Cholangitis, Sclerosing / ultrasonography. Cholecystitis / ultrasonography. Choledocholithiasis / ultrasonography. Contrast Media. Diagnosis, Differential. Endosonography. Gallbladder Neoplasms / ultrasonography. Humans. Middle Aged. Pancreatic Neoplasms / ultrasonography. Pancreatitis / ultrasonography. Polyps / ultrasonography. Sensitivity and Specificity. Ultrasonography, Doppler, Color / methods

MedlinePlus Health Information. consumer health - Pancreatic Diseases.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17323018.001).

[ISSN] 0723-5003

[Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)

[ISO-abbreviation] Med. Klin. (Munich)

[Language] ger

[Publication-type] Comparative Study; English Abstract; Journal Article; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / Contrast Media

[Number-of-references] 228

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence.

BACKGROUND: Situs inversus (SI) is a relatively rare occurrence in patients with pancreatic adenocarcinoma.

Pancreatic resection in these patients has rarely been described.

CT scan imaging is a principle modality for detecting pancreatic cancer and its use in SI patients is seldom reported.

CASE PRESENTATION: We report a 48 year old woman with SI who, despite normal CT scan 8 months earlier, presented with obstructive jaundice and a pancreatic head mass requiring a pancreaticoduodenectomy.

The surgical pathology report demonstrated pancreatic adenocarcinoma.

CONCLUSION: SI is a rare condition with concurrent pancreatic cancer being even rarer.

Additionally, radiographic imaging has significantly improved detection of early pancreatic cancer; however, there continues to be a need for improved detection of small neoplasms.

[MeSH-major] Adenocarcinoma / complications. Pancreatic Neoplasms / complications. Situs Inversus / complications

Genetic Alliance. consumer health - Situs inversus.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Eur Radiol. 2009 Oct;19(10):2448-55 [19415290.001]

[Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]

[Cites] Clin Gastroenterol Hepatol. 2008 Dec;6(12):1301-8 [18948228.001]

[Cites] Transplant Proc. 2008 Jun;40(5):1792-5 [18589199.001]

[Cites] Eur J Surg Oncol. 2007 May;33(4):524-7 [17081721.001]

[Cites] Wiad Lek. 2006;59(9-10):707-9 [17338134.001]

[Cites] Curr Opin Gastroenterol. 2006 Sep;22(5):512-9 [16891882.001]

[Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]

[Cites] Semin Cell Dev Biol. 1998 Feb;9(1):89-99 [9572118.001]

[Cites] J Clin Gastroenterol. 1997 Mar;24(2):92-6 [9077725.001]

[Cites] AJR Am J Roentgenol. 2004 Apr;182(4):897-903 [15039161.001]

[Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]

[Cites] Am J Surg. 2003 Jun;185(6):606-7 [12781900.001]

[Cites] Radiol Clin North Am. 2002 Dec;40(6):1263-72 [12479710.001]

[Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]

[Cites] Am J Med Genet. 2001 Jul 15;101(4):345-55 [11471158.001]

[Cites] Surg Radiol Anat. 2000;22(5-6):293-7 [11236325.001]

[Cites] Radiographics. 2002 Nov-Dec;22(6):1439-56 [12432114.001]

(PMID = 20021643.001).

[ISSN] 1477-7819

[Journal-full-title] World journal of surgical oncology

[ISO-abbreviation] World J Surg Oncol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC2803176

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Solitary concomitant endocrine tumor and ductal adenocarcinoma of pancreas.

Pancreatic tumors with combined exocrine and endocrine features are rare.

Most reported cases are classified as mixed exocrine and endocrine carcinoma of the pancreas.

We report the first case of solitary concomitant endocrine tumor and ductal adenocarcinoma of the pancreas.

The tumor was fortuitously discovered in the pancreatic tail after a tumor survey panel.

The exocrine part showed a poorly-differentiated adenocarcinoma.

We reviewed the literature on pancreatic tumors with combined exocrine and endocrine features.

[MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Endocrine Gland Neoplasms / pathology. Pancreatic Neoplasms / pathology

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

Hazardous Substances Data Bank. GLUCAGON .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] West J Med. 1986 Jun;144(6):746-9 [3014756.001]

[Cites] Cancer. 1984 Nov 1;54(9):1766-70 [6089999.001]

[Cites] J Gastroenterol. 1997 Aug;32(4):562-5 [9250909.001]

[Cites] Int J Pancreatol. 1999 Apr;25(2):77-87 [10360219.001]

[Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]

[Cites] Pancreas. 2005 Jul;31(1):79-83 [15968252.001]

[Cites] JOP. 2005 Sep;6(5):449-54 [16186667.001]

[Cites] Pancreatology. 2006;6(6):520-6 [17124434.001]

[Cites] Gastroenterology. 2008 Apr;134(4):981-7 [18395079.001]

[Cites] Arch Pathol Lab Med. 2000 Feb;124(2):284-6 [10656740.001]

[Cites] Int J Pancreatol. 2000 Jun;27(3):249-57 [10952408.001]

[Cites] Surg Today. 2001;31(2):177-9 [11291717.001]

[Cites] Histopathology. 2002 Aug;41(2):122-6 [12147089.001]

[Cites] Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):473-5 [15313692.001]

[Cites] Hum Pathol. 1982 Mar;13(3):263-71 [7076209.001]

[Cites] J Korean Med Sci. 1996 Apr;11(2):188-92 [8835769.001]

(PMID = 20518094.001).

[ISSN] 2219-2840

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Hypoglycemic Agents; 0 / Synaptophysin; 9007-92-5 / Glucagon

[Other-IDs] NLM/ PMC2880785

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.

A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.

We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.

In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.

In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.

It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.

[MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis

[MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged

MedlinePlus Health Information. consumer health - Cervical Cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20414103.001).

[ISSN] 1532-0979

[Journal-full-title] The American journal of surgical pathology

[ISO-abbreviation] Am. J. Surg. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma.

The aim of our study was to assess the clinical significance of -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms as well as TNF-alpha and INF-gamma serum levels in pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP) as regards to healthy volunteers.

We studied 41 patients with pancreatic adenocarcinoma, 56 with chronic pancreatitis and 50 healthy volunteers.

-308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms probably do not play important role in pancreatic diseases.

Key words: pancreatic adenocarcinoma, tumor necrosis factor alpha, interferon gamma, cytokines, polymorphism.

[MeSH-major] Adenocarcinoma / genetics. Interferon-gamma / genetics. Pancreatic Neoplasms / genetics. Tumor Necrosis Factor-alpha / genetics

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19152246.001).

[ISSN] 0028-2685

[Journal-full-title] Neoplasma

[ISO-abbreviation] Neoplasma

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Slovakia

[Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.

AIMS AND BACKGROUND: Gemcitabine is an effective agent in pancreatic adenocarcinoma.

We conducted a trial to confirm efficacy and toxicity of fixed-dose-rate gemcitabine in patients with pancreatic or biliary tree adenocarcinoma.

METHODS: Eligible patients with locally advanced or metastatic pancreatic or biliary tree adenocarcinoma received fixed-dose-rate gemcitabine at a dose of 1500 mg/m(2) at a rate of 10 mg/m(2)/min weekly for 3 weeks every 28 days.

[MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Biliary Tract Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20845800.001).

[ISSN] 0300-8916

[Journal-full-title] Tumori

[ISO-abbreviation] Tumori

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Microadenocarcinoma in the head of the pancreas.

[MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology

[MeSH-minor] Aged. Carcinoma, Neuroendocrine / diagnosis. Diagnosis, Differential. Humans. Male

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18028787.001).

[ISSN] 0366-6999

[Journal-full-title] Chinese medical journal

[ISO-abbreviation] Chin. Med. J.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] China

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion.

In this study, the expression and functional role of ADM and its signaling components were investigated in pancreatic adenocarcinoma (PDAC).

By QRT-PCR, median mRNA levels of ADM and CRLR were 1.5- and 2.4-fold higher, respectively, in PDAC tissues compared to normal pancreatic tissues.

By immunohistochemistry, ADM, CRLR, RAMP1 and RAMP2, but not RAMP3, were expressed in pancreatic cancer cells.

All 5 evaluated pancreatic cancer cells lines expressed ADM, CRLR, RAMP1 and RAMP2, whereas RAMP3 was expressed in only 1/5 pancreatic cancer cell lines.

ADM was strongly induced by hypoxia and significantly increased invasiveness in 3/5 human pancreatic cancer cells.

Blocking of CRLR decreased invasiveness in 4/5 human pancreatic cancer cells.

Furthermore, ADM increases invasiveness of some pancreatic cancer cells and might influence angiogenesis, suggesting that blocking this pathway might have a therapeutic potential.

[MeSH-major] Adrenomedullin / metabolism. Cell Hypoxia. Cell Movement. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Calcitonin Receptor-Like Protein. Cell Line. Cell Proliferation. Gene Expression Regulation, Neoplastic. Humans. Intracellular Signaling Peptides and Proteins / genetics. Membrane Proteins / genetics. Middle Aged. Neoplasm Invasiveness / pathology. Pancreas / metabolism. RNA, Messenger / genetics. Receptor Activity-Modifying Protein 1. Receptor Activity-Modifying Protein 2. Receptor Activity-Modifying Protein 3. Receptor Activity-Modifying Proteins. Receptors, Calcitonin / genetics. Signal Transduction. Transforming Growth Factor beta1 / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

Genetic Alliance. consumer health - Pancreatic cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17290391.001).

[ISSN] 0020-7136

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / CALCRL protein, human; 0 / Calcitonin Receptor-Like Protein; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RAMP1 protein, human; 0 / RAMP2 protein, human; 0 / RAMP3 protein, human; 0 / RNA, Messenger; 0 / Receptor Activity-Modifying Protein 1; 0 / Receptor Activity-Modifying Protein 2; 0 / Receptor Activity-Modifying Protein 3; 0 / Receptor Activity-Modifying Proteins; 0 / Receptors, Calcitonin; 0 / Transforming Growth Factor beta1; 0 / Vascular Endothelial Growth Factor A; 148498-78-6 / Adrenomedullin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diffusion-weighted magnetic resonance imaging of the pancreas.

The technique is more frequently used in body imaging, and recent investigations showed its use in pancreatic imaging.

Diffusion-weighted imaging can be helpful as a complementary imaging method in the differentiation between mass-forming focal pancreatitis and pancreatic adenocarcinoma.

The apparent diffusion coefficient (ADC) values derived from DWI can distinguish between simple pancreatic cyst, inflammatory cysts, and cystic neoplasms of the pancreas.

In this paper, we reviewed the technical aspects of DWI and its use in pancreatic imaging.

[MeSH-major] Cholangiopancreatography, Magnetic Resonance / methods. Cholangiopancreatography, Magnetic Resonance / trends. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Pancreas / pathology. Pancreatic Diseases / diagnosis

MedlinePlus Health Information. consumer health - Pancreatic Diseases.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19687725.001).

[ISSN] 1536-1004

[Journal-full-title] Topics in magnetic resonance imaging : TMRI

[ISO-abbreviation] Top Magn Reson Imaging

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 28

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas.

The expression of claudin-4 was investigated in human pancreas, pancreatic ductal adenocarcinomas, and intraductal papillary-mucinous tumors of the pancreas (IPMT), and compared with that of claudin-1.

In human adult pancreatic specimens, both claudin-1 and claudin-4 were immunohistochemically found in main and branching pancreatic ducts, terminal ductules and acinic cells, with the exception of endocrine cells.

Of 12 cases of pancreatic ductal adenocarcinoma, 11 (92%) had positive immunostaining for claudin-4, and seven (58%) for claudin-1.

[MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Papillary / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Membrane Proteins / metabolism. Pancreatic Neoplasms / metabolism

[MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Claudin-1. Claudin-4. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Pancreas / metabolism. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15693851.001).

[ISSN] 1320-5463

[Journal-full-title] Pathology international

[ISO-abbreviation] Pathol. Int.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Australia

[Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Update on pancreatic intraepithelial neoplasia.

Pancreatic intraepithelial neoplasia (PanIN) is a histologically well-defined precursor to invasive ductal adenocarcinoma of the pancreas.

Molecular studies have helped establish the progression of PanIN to invasive cancer, and recently genetically engineered mouse models have been generated that recapitulate the entire spectrum of lesions from precursor to invasive pancreatic cancer.

Some PanIN lesions produce lobulocentric atrophy of the pancreatic parenchyma, and, when multifocal, this lobulocentric atrophy may be detectable using currently available imaging techniques such as endoscopic ultrasound.

COS Scholar Universe. author profiles.

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]

[Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]

[Cites] Nat Methods. 2004 Nov;1(2):141-7 [15782177.001]

[Cites] Am J Surg Pathol. 2003 Dec;27(12):1495-501 [14657708.001]

[Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]

[Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):622-5 [12697855.001]

[Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83 [12673124.001]

[Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]

[Cites] Cancer Biol Ther. 2002 May-Jun;1(3):293-6 [12432281.001]

[Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]

[Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]

[Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]

[Cites] Am J Clin Pathol. 2002 Aug;118(2):194-201 [12162677.001]

[Cites] Am J Pathol. 2002 May;160(5):1573-81 [12000709.001]

[Cites] Mol Cell Biol. 2002 Jan;22(2):635-43 [11756558.001]

[Cites] Am J Surg Pathol. 2001 Aug;25(8):1047-53 [11474289.001]

[Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]

[Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]

[Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]

[Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]

[Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]

[Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]

[Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]

[Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]

[Cites] JAMA. 2000 Oct 18;284(15):1954-61 [11035892.001]

[Cites] Am J Pathol. 2000 Jul;157(1):83-92 [10880379.001]

[Cites] Am J Pathol. 2000 Jun;156(6):2123-33 [10854233.001]

[Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]

[Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]

[Cites] Cancer Res. 2000 Apr 1;60(7):1835-9 [10766168.001]

[Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]

[Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]

[Cites] Cancer. 1999 Apr 15;85(8):1703-10 [10223563.001]

[Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]

[Cites] Ann Diagn Pathol. 1998 Oct;2(5):286-92 [9845751.001]

[Cites] Cancer Res. 1998 Oct 15;58(20):4740-4 [9788631.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):515-21 [9641496.001]

[Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]

[Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]

[Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]

[Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]

[Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]

[Cites] Gastroenterology. 1996 Jan;110(1):227-31 [8536861.001]

[Cites] Nat Genet. 1994 Sep;8(1):27-32 [7726912.001]

[Cites] Cancer Res. 1994 Jul 1;54(13):3568-73 [8012983.001]

[Cites] Cancer Res. 1993 Mar 1;53(5):953-6 [8439969.001]

[Cites] Cancer. 1979 Apr;43(4):1418-28 [445339.001]

[Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]

[Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]

[Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]

[Cites] Gastroenterology. 2004 Jun;126(7):1674-80 [15188160.001]

[Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]

[Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]

[Cites] Mol Imaging. 2007 Mar-Apr;6(2):131-9 [17445507.001]

[Cites] Cancer Res. 2007 Aug 1;67(15):7068-71 [17652141.001]

[Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]

[Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]

[Cites] Am J Surg Pathol. 2007 Apr;31(4):645-6 [17414117.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]

[Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]

[Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]

[Cites] Cancer Cell. 2007 Mar;11(3):211-3 [17349578.001]

[Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]

[Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]

[Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]

[Cites] Clin Cancer Res. 2006 Sep 15;12(18):5417-22 [17000675.001]

[Cites] Clin Cancer Res. 2006 Sep 15;12(18):5411-6 [17000674.001]

[Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]

[Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):286-95 [16858539.001]

[Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]

[Cites] Am J Surg Pathol. 2006 Jun;30(6):754-9 [16723855.001]

[Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]

[Cites] Cancer Res. 2006 Jan 1;66(1):242-7 [16397237.001]

[Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]

[Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]

[Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]

[Cites] N Engl J Med. 2005 Oct 27;353(17):1784-92 [16251534.001]

(PMID = 18787611.001).

[ISSN] 1936-2625

[Journal-full-title] International journal of clinical and experimental pathology

[ISO-abbreviation] Int J Clin Exp Pathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2480542

[Keywords] NOTNLM ; Pancreatic cancer / epigenetics / genetics / intraepithelial neoplasm / metaplasia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A case of primary ductal adenocarcinoma of the lacrimal gland: histopathological and immunohistochemical study.

We encountered primary ductal adenocarcinoma of the lacrimal gland in a 67-year-old Japanese man.

To the best of our knowledge, only three cases of primary ductal adenocarcinoma of the lacrimal gland have been reported in the literature.

The mass was resected, and primary ductal adenocarcinoma of the lacrimal gland was diagnosed histopathologically.

He died from recurrence at the primary site and metastasis to the brain, lungs, liver, common bile duct, and pancreas 2 years and 10 months after surgery although adjunctive orbital radiotherapy was given.

It was not clear whether the ductal adenocarcinoma originated from the ductal or acinar epithelium of the lacrimal gland, because the immunohistochemical features of both epithelia were identical.

MedlinePlus Health Information. consumer health - Eye Cancer.

MedlinePlus Health Information. consumer health - Tears.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15807311.001).

[ISSN] 0344-0338

[Journal-full-title] Pathology, research and practice

[ISO-abbreviation] Pathol. Res. Pract.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Germany

[Chemical-registry-number] 68238-35-7 / Keratins

[Number-of-references] 14

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.

BACKGROUND: Pancreatic cancer continues to prove difficult to clinically diagnose.

Multiple simultaneous measurements of plasma biomarkers can increase sensitivity and selectivity of diagnosis.

METHODS: We examined the plasma levels of 21 biomarkers in a clinically defined cohort of 52 locally advanced (Stage II/III) pancreatic ductal adenocarcinoma cases and 43 age-matched controls using a multiplex proximity ligation assay.

The optimal biomarker panel for diagnosis was computed using a combination of the PAM algorithm and logistic regression modeling.

RESULTS: Three markers, CA19-9, OPN and CHI3L1, measured in multiplex were found to have superior sensitivity for pancreatic cancer vs. CA19-9 alone (93% vs. 80%).

In addition, we identified two markers, CEA and CA125, that when measured simultaneously have prognostic significance for survival for this clinical stage of pancreatic cancer (p < 0.003).

CONCLUSIONS: A multiplex panel assaying CA19-9, OPN and CHI3L1 in plasma improves accuracy of pancreatic cancer diagnosis.

A panel assaying CEA and CA125 in plasma can predict survival for this clinical cohort of pancreatic cancer patients.

Genetic Alliance. consumer health - Pancreatic cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2006 Nov 20;24(33):5291-7 [17114663.001]

[Cites] Cancer Biomark. 2005;1(6):259-69 [17192050.001]

[Cites] Expert Opin Ther Targets. 2007 Feb;11(2):219-34 [17227236.001]

[Cites] Nat Methods. 2007 Apr;4(4):327-9 [17369836.001]

[Cites] Clin Chem. 2008 Mar;54(3):582-9 [18171715.001]

[Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]

[Cites] Cancer Metastasis Rev. 2008 Sep;27(3):351-62 [18483785.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81 [18843033.001]

[Cites] J Clin Oncol. 2008 Oct 10;26(29):4771-6 [18779603.001]

[Cites] Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):333-45 [18952487.001]

[Cites] J Clin Oncol. 2009 Feb 1;27(4):572-8 [19075264.001]

[Cites] Nat Biotechnol. 2002 May;20(5):473-7 [11981560.001]

[Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]

[Cites] Oncogene. 2009 Sep 24;28(38):3412-22 [19597469.001]

[Cites] BMC Cancer. 2009;9:8 [19134206.001]

[Cites] Clin Cancer Res. 2003 Jan;9(1):59-67 [12538452.001]

[Cites] Acta Obstet Gynecol Scand. 2003 Mar;82(3):287-93 [12694127.001]

[Cites] Breast Cancer Res Treat. 2003 Jul;80(1):15-21 [12889595.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8420-4 [15155907.001]

[Cites] Cancer Res. 1983 Nov;43(11):5489-92 [6193872.001]

[Cites] Cancer. 1988 Dec 1;62(11):2287-90 [3179943.001]

[Cites] Pancreas. 1994 Nov;9(6):735-40 [7846017.001]

[Cites] Eur J Cancer. 1995;31A(9):1437-42 [7577068.001]

[Cites] Clin Chem. 1997 Sep;43(9):1749-56 [9299971.001]

[Cites] Br J Cancer. 1999 Mar;79(9-10):1494-9 [10188896.001]

[Cites] Eur J Surg Oncol. 2005 Mar;31(2):164-9 [15698733.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18 [15734951.001]

[Cites] J Clin Oncol. 2005 Jul 10;23(20):4524-31 [16002843.001]

[Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]

(PMID = 20003342.001).

[ISSN] 1479-5876

[Journal-full-title] Journal of translational medicine

[ISO-abbreviation] J Transl Med

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P01 CA67166

[Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Other-IDs] NLM/ PMC2796647

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-major] Adenocarcinoma, Mucinous / classification. Bile Duct Neoplasms / classification. Bile Ducts, Intrahepatic / radiography. Cholangiography / methods. Precancerous Conditions / classification

MedlinePlus Health Information. consumer health - Bile Duct Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Pancreas. 2005 Apr;30(3):233-8 [15782100.001]

[Cites] Br J Surg. 1998 Sep;85(9):1206-9 [9752860.001]

[Cites] Hepatology. 2000 Jan;31(1):12-7 [10613721.001]

[Cites] Dig Dis Sci. 2000 Feb;45(2):312-6 [10711444.001]

[Cites] Ann Surg. 2000 Aug;232(2):166-74 [10903592.001]

[Cites] AJR Am J Roentgenol. 2000 Sep;175(3):721-5 [10954456.001]

[Cites] AJR Am J Roentgenol. 2000 Oct;175(4):1135-9 [11000178.001]

[Cites] Hepatology. 2001 Oct;34(4 Pt 1):651-8 [11584359.001]

[Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]

[Cites] Br J Surg. 2004 Jan;91(1):99-104 [14716802.001]

[Cites] Radiographics. 2004 Jan-Feb;24(1):53-66; discussion 66-7 [14730036.001]

[Cites] Am J Surg Pathol. 2004 Mar;28(3):327-38 [15104295.001]

[Cites] Cancer. 1993 Apr 15;71(8):2461-5 [8384069.001]

[Cites] Surgery. 1996 Sep;120(3):509-14 [8784405.001]

[Cites] Ann Surg. 1998 Jan;227(1):63-9 [9445112.001]

[Cites] Gastroenterology. 2005 May;128(6):1655-67 [15887157.001]

(PMID = 16858187.001).

[ISSN] 0003-4932

[Journal-full-title] Annals of surgery

[ISO-abbreviation] Ann. Surg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC1602176

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Medical management of pancreatic adenocarcinoma.

Pancreatic cancer is the fourth leading cause of cancer death in the United States.

In 2008, an estimated 34,290 people died from pancreatic cancer and 37,680 new cases were diagnosed.

Despite modern treatment, 90% of patients die within 1 year of diagnosis.

In the present paper the English-language literature addressing the medical management in pancreatic cancer was reviewed.

Based on these data we will discuss the role of currently used chemotherapy and target therapy in pancreatic cancer, as well as perspectives of the emerging strategies that are arising in order to improve the outcomes of this complex disease.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

Hazardous Substances Data Bank. CAPECITABINE .

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2009 S. Karger AG, Basel.

(PMID = 19420981.001).

[ISSN] 1424-3911

[Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

[ISO-abbreviation] Pancreatology

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil

[Number-of-references] 112

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Resection of the celiac axis increase resectability rate in locally advanced pancreatic body and gastric tumor].

[Transliterated title] Rezectia de trunchi celiac--factor de creştere a rezecabilităţii in neoplasmele pancreatice si gastrice local avansate.

Carcinoma of the body and tail of the pancreas is often diagnosed at an advanced stage or metastatic stage.

[MeSH-major] Adenocarcinoma / surgery. Celiac Artery / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

MedlinePlus Health Information. consumer health - Stomach Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16927919.001).

[ISSN] 1221-9118

[Journal-full-title] Chirurgia (Bucharest, Romania : 1990)

[ISO-abbreviation] Chirurgia (Bucur)

[Language] rum

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Romania

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes.

We investigated the ability of the zinc chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) to reduce pancreatic cancer cell viability.

TPEN was much more efficient to inhibit pancreatic adenocarcinoma cell growth than a panel of anti-cancer drugs, including 5-fluorouracil, irinotecan, cisplatin, edelfosine, trichostatin A, mitomycin C, and gemcitabine, the gold standard chemotherapeutic agent for pancreatic cancer.

Moreover, TPEN showed a dose- and time-dependent anti-proliferative effect significantly higher on pancreatic cancer cells than on normal primary fibroblasts.

This effect may be explained by a significantly higher zinc depletion by TPEN in pancreatic cancer cells as compared to fibroblasts.

In this study, we suggest that zinc depletion may be an efficient strategy in the treatment of pancreatic cancer because of its reduced antiproliferative effect on normal cells.

[MeSH-major] Cell Proliferation / drug effects. Ethylenediamines / pharmacology. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / therapy. Zinc / deficiency

Genetic Alliance. consumer health - Pancreatic cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

Hazardous Substances Data Bank. ZINC, ELEMENTAL .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17979179.001).

[ISSN] 1097-4644

[Journal-full-title] Journal of cellular biochemistry

[ISO-abbreviation] J. Cell. Biochem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Chelating Agents; 0 / Ethylenediamines; 16858-02-9 / N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine; J41CSQ7QDS / Zinc

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We report on a 61-year-old male who underwent explorative laparotomy for pancreatic tumour.

Intraoperatively, the diagnosis of a locally advanced carcinoma of the head of the pancreas was confirmed histologically.

[MeSH-major] Adenocarcinoma / surgery. Edema / surgery. Inguinal Canal / surgery. Pancreatic Neoplasms / surgery. Pancreatitis, Acute Necrotizing / surgery. Postoperative Complications / surgery

[MeSH-minor] Abdominal Abscess / diagnosis. Abdominal Abscess / pathology. Abdominal Abscess / surgery. Diagnosis, Differential. Hernia, Inguinal / diagnosis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Reoperation

Genetic Alliance. consumer health - Pancreatitis.

MedlinePlus Health Information. consumer health - After Surgery.

MedlinePlus Health Information. consumer health - Edema.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19382054.001).

[ISSN] 0044-409X

[Journal-full-title] Zentralblatt für Chirurgie

[ISO-abbreviation] Zentralbl Chir

[Language] ger

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

PURPOSE: Patients with advanced pancreas cancer present with disease that is poorly responsive to conventional therapies.

Preclinical and early clinical evidence has supported targeting the epidermal growth factor receptor (EGFR) signaling pathway in patients with pancreas cancer.

PATIENTS AND METHODS: Patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma were randomly assigned to receive gemcitabine alone or gemcitabine plus cetuximab.

CONCLUSION: In patients with advanced pancreas cancer, the anti-EGFR monoclonal antibody cetuximab did not improve the outcome compared with patients treated with gemcitabine alone.

[MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. CETUXIMAB .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]

[Cites] Cancer Res. 2000 Jun 1;60(11):2926-35 [10850439.001]

[Cites] Cancer. 2000 Jul 1;89(1):74-82 [10897003.001]

[Cites] Cancer Invest. 2003;21(1):73-86 [12643012.001]

[Cites] Pancreas. 2004 Jul;29(1):e1-8 [15211117.001]

[Cites] J Clin Oncol. 2004 Jul 1;22(13):2610-6 [15226328.001]

[Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]

[Cites] Anticancer Res. 1993 May-Jun;13(3):565-9 [8317885.001]

[Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]

[Cites] Cancer. 2006 Aug 15;107(4):676-85 [16847885.001]

[Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]

[Cites] Lancet Oncol. 2008 Jan;9(1):39-44 [18077217.001]

[Cites] Lancet Oncol. 2008 Jan;9(1):7-8 [18177814.001]

[Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]

[Cites] Cell Mol Life Sci. 2008 May;65(10):1566-84 [18259690.001]

[Cites] Br J Cancer. 2008 Jul 8;99(1):1-5 [18506149.001]

[CommentIn] J Clin Oncol. 2011 Jan 20;29(3):e70-1; author reply e72-3 [21149660.001]

(PMID = 20606093.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00075686

[Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / U10 CA035128; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA035192; United States / NCI NIH HHS / CA / U10 CA077202; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / U10 CA014028; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / U10 CA035281; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / U10 CA045461; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / U10 CA091105; United States / NCI NIH HHS / CA / U10 CA045450; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / U10 CA035262; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / U10 CA095860; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA067663; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / U10 CA058861; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560

[Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; PQX0D8J21J / Cetuximab

[Other-IDs] NLM/ PMC2917315

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pancreatic adenocarcinoma: analysis of the effect of various concentrations of contrast material.

PURPOSE: The aim of this study was to compare the efficacy of two contrast materials with moderate and high iodine concentrations for the depiction of pancreatic adenocarcinoma.

MATERIALS AND METHODS: A series of 107 patients with histologically proven pancreatic adenocarcinoma underwent helical computed tomography.

We evaluated enhancement of the aorta, portal vein, hepatic parenchyma, pancreatic parenchyma, and pancreatic adenocarcinoma during each phase.

RESULTS: During all phases, both aortic and pancreatic enhancement were significantly greater in group B than in group A (P<0.01).

Tumor-to-pancreas contrast was significantly greater in group B than in group A at both 30 s (P<0.01) and 70 s (P<0.05).

CONCLUSION: Administration of contrast material with a high iodine concentration is more effective for depicting pancreatic adenocarcinomas.

[MeSH-major] Adenocarcinoma / diagnostic imaging. Contrast Media / administration & dosage. Iopamidol / administration & dosage. Pancreatic Neoplasms / diagnostic imaging

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]

[Cites] Radiat Med. 2003 Mar-Apr;21(2):74-9 [12816354.001]

[Cites] AJR Am J Roentgenol. 1994 Jun;162(6):1425-9 [8192012.001]

[Cites] AJR Am J Roentgenol. 2006 Feb;186(2):406-15 [16423946.001]

[Cites] Radiology. 1995 Oct;197(1):89-93 [7568860.001]

[Cites] Radiology. 1999 Jan;210(1):97-101 [9885593.001]

[Cites] Radiology. 1995 Apr;195(1):1-8 [7892446.001]

[Cites] Radiology. 1992 May;183(2):297-303 [1561324.001]

[Cites] AJR Am J Roentgenol. 2006 Feb;186(2):379-85 [16423942.001]

[Cites] Radiology. 1999 Aug;212(2):445-52 [10429702.001]

[Cites] AJR Am J Roentgenol. 1996 Jul;167(1):49-55 [8659419.001]

[Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]

[Cites] Cancer. 1995 Nov 1;76(9):1671-7 [8635074.001]

[Cites] AJR Am J Roentgenol. 2002 Apr;178(4):821-6 [11906855.001]

[Cites] Radiology. 1998 Feb;206(2):373-8 [9457188.001]

[Cites] Radiology. 2000 Sep;216(3):718-23 [10966700.001]

[Cites] Radiology. 1998 Feb;206(2):455-64 [9457200.001]

[Cites] Radiology. 2000 Aug;216(2):403-9 [10924561.001]

[Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]

[Cites] AJR Am J Roentgenol. 2005 May;184(5):1535-40 [15855112.001]

[Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):582-7 [16163023.001]

[Cites] Radiology. 1997 Mar;202(3):655-62 [9051012.001]

[Cites] Radiology. 1995 May;195(2):353-7 [7724752.001]

[Cites] Br J Radiol. 2004 Oct;77(922):821-30 [15482993.001]

[Cites] Radiology. 1999 Jul;212(1):219-25 [10405745.001]

[Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]

[Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]

(PMID = 18677610.001).

[ISSN] 0288-2043

[Journal-full-title] Radiation medicine

[ISO-abbreviation] Radiat Med

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Contrast Media; JR13W81H44 / Iopamidol